Try Ask OE! Our NEW Advanced AI Enabled Search
Dive into the Largest Database of
Musculoskeletal Evidence
ACE Reports.
Pediatric Orthopaedics
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study
J Clin Endocrinol Metab. 2011 Feb;96(2):355-64
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study
This report has been verified by one or more authors of the original publication.
J Clin Endocrinol Metab. 2011 Feb;96(2):355-64
Pediatric Orthopaedics
Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial
Lancet. 2013 Aug 5. pii: S0140-6736(13)61091-0.
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial
Lancet. 2013 Aug 5. pii: S0140-6736(13)61091-0.